Exagen Inc. Reports Q2 2025 Revenue Growth Amid Rising Losses and Operational Challenges

Exagen Inc. (NASDAQ: XGN) - Q2 2025 Financial Overview

Exagen Inc. continues its focus on autoimmune diagnostic testing, reporting notable developments and financial results from its Q2 2025 earnings report. The company aims to improve its offering through innovations while navigating financial challenges.

Key Financial Highlights:

• Revenue: $17.2 million for Q2 2025, up 14.2% from $15.1 million in Q2 2024.
• Cost of Revenue: Increased to $6.8 million, a 13.3% rise compared to $6.0 million in Q2 2024.
• Gross Margin: Slightly increased to 60.4% from 60.1% year-over-year.
• Operating Expenses: Totaled $13.0 million in Q2 2025, a 12% increase from $11.6 million in Q2 2024.
• Net Loss: Expanded to $4.4 million in Q2 2025 from $3.0 million in Q2 2024 (loss per share of $0.21).

Positive Aspects:

• Revenue growth driven by an increase in average sales prices (ASP) due to new biomarker additions.
• Strong cash position of $30.0 million as of June 30, 2025, which provides a cushion for operations and growth initiatives.

Negative Aspects:

• Operating expenses rose, leading to ongoing losses, raising questions about sustainability in the near term.
• Accounts receivable increased significantly, indicating challenges in cash collection and potential liquidity strains.

Recent Developments:

• On April 25, 2025, Exagen secured a $75 million term loan from Perceptive Credit Holdings, bolstering its financing strategy.
• The company issued 3,852,500 shares in a public offering, generating $18.6 million in net proceeds to assist in growth and operational costs.
• Focus on rolling out new biomarker products aimed to enhance detection rates for autoimmune diseases.

This report outlines Exagen's concerted efforts to enhance its market position through innovative testing products while navigating the complexities of revenue generation and operational expenses. The attention to growth initiatives and strategic financing is crucial for the company's trajectory.